Yuishin Izumi

Yuishin Izumi

Auto-generated profile, based on publicly available information

Yuishin Izumi

Department of Neurology, Tokushima University, Tokushima, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
RORyosuke Oki
Ryosuke Oki
YIYuishin Izumi
Yuishin Izumi
KFKoji Fujita
Koji Fujita
RMRyosuke Miyamoto
Ryosuke Miyamoto
HNHiroyuki Nodera
Hiroyuki Nodera
YFYukio Fujino
Yukio Fujino
Amyotrophic lateral sclerosis (ALS) is an intractable disease affecting the upper and lower motor neurons and resulting in progressive systemic muscle weakness and atrophy. The duration from symptom onset to the use of invasive respiratory support or death is 20 to 48 months.1 Although riluzole2,3 and edaravone4 have been approved by the US Food and Drug Administration to modify the disease progression of ALS, the effectiveness of these drugs is restricted, warranting the development of further treatments.

26 December 2015 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HNHiroyuki Nodera
Hiroyuki Nodera
NTN. Takamatsu
N. Takamatsu
NMN. Matsui
N. Matsui
AMA. Mori
A. Mori
YTY. Terasawa
Y. Terasawa
RKR. Kaji
R. Kaji

1 March 2016 in eNeurologicalSci
Verified
Journal Article
Open access
WSWaka Sakai
Waka Sakai
NMNaoko Matsui
Naoko Matsui
MIMitsuyo Ishida
Mitsuyo Ishida
TFTakahiro Furukawa
Takahiro Furukawa
YMYoshimichi Miyazaki
Yoshimichi Miyazaki
Ryuji KajiRyuji Kaji
Ryuji Kaji
The continuous increase in the number of patients presenting with late-onset myasthenia gravis (LOMG) underscores the need for a better understanding of the clinical course and the establishment of an optimal therapeutic strategy. We aimed to clarify factors associated with clinical outcomes in LOMG. We retrospectively reviewed the clinical profiles of 40 patients with early-onset MG (EOMG) (onset age: 49 years or younger), 30 patients with non-elderly LOMG (onset age: 50-64 years), and 28 patients with elderly LOMG (onset age: 65 years or older) and compared the subgroups according to onset age and thymus status. The evaluated parameters were MGFA classification before treatment, MG-ADL score, complicating diseases, antibody titer, treatment, and MGFA post-intervention status. Elderly LOMG patients showed transition to generalized symptoms at a higher frequency and underwent thymectomy less frequently than EOMG and non-elderly LOMG patients (p < 0.001). The frequencies of crisis and plasmapheresis were significantly lower in thymectomized LOMG patients without thymoma than in thymectomized LOMG patients with thymoma or non-thymectomized LOMG patients (p < 0.01, P < 0.05, respectively). However, the outcome was not significantly different. All of the thymectomized LOMG patients without thymoma presenting with hyperplasia or thymic cyst had a favorable clinical course. Our study showed that elderly LOMG patients are more prone to severity, suggesting that they require aggressive immunomodulatory therapy.

27 December 2022 in Life
Verified
Journal Article
Open access
PDF file
JFJoji Fujikawa
Joji Fujikawa
Ryoma MorigakiRyoma Morigaki
Ryoma Morigaki
NYNobuaki Yamamoto
Nobuaki Yamamoto
HNHiroshi Nakanishi
Hiroshi Nakanishi
TOTeruo Oda
Teruo Oda
YTYasushi Takagi
Yasushi Takagi
Background: Parkinsonian tremors are sometimes confused with essential tremors or other conditions. Recently, researchers conducted several studies on tremor evaluation using wearable sensors and devices, which may support accurate diagnosis. Mechanical devices are also commonly used to treat tremors and have been actively researched and developed. Here, we aimed to review recent progress and the efficacy of the devices related to Parkinsonian tremors. Methods: The PubMed and Scopus databases were searched for articles. We searched for “Parkinson disease” and “tremor” and “device”. Results: Eighty-six articles were selected by our systematic approach. Many studies demonstrated that the diagnosis and evaluation of tremors in patients with PD can be done accurately by machine learning algorithms. Mechanical devices for tremor suppression include deep brain stimulation (DBS), electrical muscle stimulation, and orthosis. In recent years, adaptive DBS and optimization of stimulation parameters have been studied to further improve treatment efficacy. Conclusions: Due to developments using state-of-the-art techniques, effectiveness in diagnosing and evaluating tremor and suppressing it using these devices is satisfactorily high in many studies. However, other than DBS, no devices are in practical use. To acquire high-level evidence, large-scale studies and randomized controlled trials are needed for these devices.

11 October 2018 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
PDF file
YIYuishin Izumi
Yuishin Izumi
HMHiroyuki Morino
Hiroyuki Morino
RMRyosuke Miyamoto
Ryosuke Miyamoto
YMYukiko Matsuda
Yukiko Matsuda
RORyosuke Ohsawa
Ryosuke Ohsawa
HKHideshi Kawakami
Hideshi Kawakami

22 April 2013 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
PDF file
TNTomokazu Nishikawa
Tomokazu Nishikawa
TTTetsuya Takahashi
Tetsuya Takahashi
MNMasahiro Nakamori
Masahiro Nakamori
YYYu Yamazaki
Yu Yamazaki
TKTakashi Kurashige
Takashi Kurashige
MMMasayasu Matsumoto
Masayasu Matsumoto
Aims: Among the pathological findings in Alzheimer's disease (AD), the temporal and spatial profiles of granulovacuolar degeneration (GVD) bodies are characteristic in that they seem to be related to those of neurofibrillary tangles (NFTs), suggesting a common mechanism underlying the pathogenesis of these structures. Flotillin‐1, a marker of lipid rafts, accumulates in lysosomes of tangle‐bearing neurones in AD patients. In addition, recent reports have shown that GVD bodies accumulate at the nexus of the autophagic and endocytic pathways. The aim of this study was to elucidate the distribution of the lipid component of lipid rafts, phosphatidylinositol‐4,5‐bisphosphate [PtdIns(4,5)P2], in AD and other neurodegenerative disorders.Methods: We compared PtdIns(4,5)P2 immunoreactivity in the hippocampus, entorhinal cortex and neocortex of five AD cases, 17 cases of other neurodegenerative disorders and four controls. In addition, we performed double staining using markers of GVD, NFTs and lipid rafts for further characterization.Results: Immunohistochemical analysis revealed that PtdIns(4,5)P2 was selectively enriched in GVD bodies and NFTs. Although immunoreactivity for PtdIns(4,5)P2 was also evident in NFTs composed of hyperphosphorylated tau, PtdIns(4,5)P2 was segregated from phosphorylated tau within NFTs by double immunofluorescence staining. In contrast, PtdIns(4,5)P2 colocalized with the lipid raft markers flotillin‐1 and annexin 2, within GVD bodies and NFTs.Conclusions: These results suggest that lipid raft components including PtdIns(4,5)P2 play a role in the formation of both GVD bodies and NFTs.